secwatch / observer
8-K filed December 5, 2022, 6:59 PM ET ticker EVTC CIK 0001559865
debt confidence high sentiment positive materiality 0.60

EVERTEC, Inc. (EVTC): debt financing — EVERTEC refinances credit facilities with $415M term loan A and $200M revolver due Dec 2027

EVERTEC, Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

EVERTEC, Inc. incurred revolving credit of $200.0 million revolving credit facility with Truist Bank, as administrative agent and collateral agent at Adjusted Term SOFR plus an applicable margin of 1.50% per annum maturing December 1, 2027.

Instrument
revolving credit
Principal
$200.0 million revolving credit facility
Counterparty
Truist Bank, as administrative agent and collateral agent
Rate
Adjusted Term SOFR plus an applicable margin of 1.50% per annum
Maturity
December 1, 2027
Event
incurrence
Exact text from the filing
On December 1, 2022 (the “Closing Date”), EVERTEC, Inc., (“EVERTEC” or the “Company”) and EVERTEC Group, LLC, (“EVERTEC Group” or “Borrower”), a wholly owned indirect subsidiary of EVERTEC, entered into a credit agreement (the “Credit Agreement”) with a syndicate of lenders and Truist Bank (“Truist”), as administrative agent and collateral agent, providing for (i) a $415.0 million term loan A facility (the “Term Loan Facility”) and (ii) a $200.0 million revolving credit facility (the “Revolving Facility”, and together with the Term Loan Facility, the “2022 Credit Facilities”).
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

EVERTEC, Inc. incurred term loan of $415.0 million term loan A facility with Truist Bank, as administrative agent and collateral agent at Adjusted Term SOFR plus an applicable margin of 1.50% per annum maturing December 1, 2027.

Instrument
term loan
Principal
$415.0 million term loan A facility
Counterparty
Truist Bank, as administrative agent and collateral agent
Rate
Adjusted Term SOFR plus an applicable margin of 1.50% per annum
Maturity
December 1, 2027
Event
incurrence
Exact text from the filing
On December 1, 2022 (the “Closing Date”), EVERTEC, Inc., (“EVERTEC” or the “Company”) and EVERTEC Group, LLC, (“EVERTEC Group” or “Borrower”), a wholly owned indirect subsidiary of EVERTEC, entered into a credit agreement (the “Credit Agreement”) with a syndicate of lenders and Truist Bank (“Truist”), as administrative agent and collateral agent, providing for (i) a $415.0 million term loan A facility (the “Term Loan Facility”) and (ii) a $200.0 million revolving credit facility (the “Revolving Facility”, and together with the Term Loan Facility, the “2022 Credit Facilities”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

EVERTEC, Inc. entered into Credit Agreement with Truist Bank valued at $415.0 million term loan A facility and $200.0 million revolving credit facility (effective 2022-12-01).

Action
entry
Agreement
credit facility
Counterparty
Truist Bank
Value
$415.0 million term loan A facility and $200.0 million revolving credit facility
Effective
2022-12-01
Exact text from the filing
On December 1, 2022 (the “Closing Date”), EVERTEC, Inc., (“EVERTEC” or the “Company”) and EVERTEC Group, LLC, (“EVERTEC Group” or “Borrower”), a wholly owned indirect subsidiary of EVERTEC, entered into a credit agreement (the “Credit Agreement”) with a syndicate of lenders and Truist Bank (“Truist”), as administrative agent and collateral agent, providing for (i) a $415.0 million term loan A facility (the “Term Loan Facility”) and (ii) a $200.0 million revolving credit facility (the “Revolving Facility”, and together with the Term Loan Facility, the “2022 Credit Facilities”).
View on SEC.gov

Browse all debt financings →

EVERTEC, Inc. filing history →

Source: SEC EDGAR
accession 0001140361-22-044293
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.